Open House - Global Healthcare 2022: Avalo Therapeutics | Edison Group
Avalo is a clinical-stage precision medicine company that discovers, develops, and commercializes targeted therapeutics for patients with significant unmet clinical need in the areas of immunology, immuno-oncology and rare disease.
-
Michael Cola, Chief Executive, Avalo Therapeutics
Prior to joining Avalo, Mr. Cola served as President and CEO of Aevi Genomic Medicine since September 2013. Prior to joining Aevi Genomic Medicine, Mr. Cola served as President of Specialty Pharmaceuticals at Shire plc. He joined Shire in 2005 as EVP of Global Therapeutic Business Units and Portfolio Management. Prior to Shire, he was with Safeguard Scientifics, Inc., where he served as President of the Life Sciences Group. While at Safeguard, Mr. Cola served as Chairman and CEO of Clarient, Inc., a cancer diagnostics company subsequently acquired by GE Healthcare, and as Chairman of Laureate Pharma, Inc. Previously, Mr. Cola held senior positions in product development and commercialization at Astra Merck, a top 20 US pharmaceutical company, and at AstraZeneca.
